Compliance & Regulation

Preparing for CVSSv4: why manufacturers must act now

The FDA's move toward CVSSv4 by 2027 is closer than it looks, and it is not a cosmetic change. CVSSv4 introduced subsequent-system impact, which rewards exactly the kind of chained analysis most programs are not doing yet.

Info leakLOW+Auth bypassMEDIUM+Memory bugMEDIUM=Full chainCRITICAL
CVSSv4 subsequent impact: low plus medium plus medium is not three small problems. It is one critical path.

A low-severity information leak, plus a reachable authentication bypass, plus a memory-safety bug, is not three medium problems you can defer. It is one critical path through the device. Score them in isolation and you will both over-patch the harmless ones and miss the chain that matters.

What to do before the deadline forces it

Start modeling attack paths now. Map initial access points, trace what each finding produces and what the next one requires, and score the chain, not the node. Manufacturers who wait until 2027 will be migrating ratings under audit pressure. The ones who start now get quieter backlogs immediately, because chaining also tells you which single fix collapses the most risk.

CVSSv4 is not more paperwork. It is the score finally matching how real attacks work.
← All intelligence
Get started

See your device through ELTON.

Start with one device. We build the twin from documentation your quality system already produces, run AI discovery remotely, and show you the graph: the handful to fix, and the evidence for everything else.

Proof Over Probability

The AI testing newsletter.

One issue a month on AI, exploitability, and FDA cybersecurity review. No spam, unsubscribe anytime.

Questions

Common questions about the CVSSv4 migration.

What changed in CVSSv4 that matters for medical devices?

CVSSv4 introduced subsequent-system impact, which rewards chained analysis. A low-severity information leak, plus a reachable authentication bypass, plus a memory-safety bug, is not three medium problems you can defer. It is one critical path through the device, and the new scoring finally says so.

When does the FDA expect manufacturers to move to CVSSv4?

The FDA's move toward CVSSv4 by 2027 is closer than it looks, and it is not a cosmetic change. Manufacturers who wait will be migrating ratings under audit pressure. The ones who start now get quieter backlogs immediately.

What goes wrong when you score vulnerabilities in isolation?

Two things at once. Scoring node by node means over-patching the harmless findings and missing the chain that matters. The severity of a chain is not the sum of its parts, which is exactly what subsequent-system impact was added to capture.

How do you prepare for CVSSv4 before the deadline?

Start modeling attack paths now. Map initial access points, trace what each finding produces and what the next one requires, and score the chain rather than the node. Chaining also tells you which single fix collapses the most risk, so the backlog gets shorter while the analysis gets better.

Is CVSSv4 just more paperwork?

No. CVSSv4 is the score finally matching how real attacks work. Subsequent-system impact makes the rating reflect what an attacker reaches after the first step, which is the kind of chained analysis most programs are not doing yet. The same analysis produces a quieter backlog, because it shows which single fix collapses the most risk.

Exploitability management for medical devices. FDA §524B methodologyExploitability proven at runtime95% faster than legacy testing Book a Demo
Platform
OverviewAvoid FDA DeficienciesAvoid Consulting FeesDigital Twin TraceabilityAI PentestingExploitability VerificationVulnerability ChainingRemediation OptimizationRemote TestLink™Incident ResponseAutomated VEX & MetricsCVSSv4 Migration
Solutions
Postmarket SurveillanceIncident ResponseSecurity EngineeringRegulatory AffairsFDA §524BEU MDR/CRAEU REDNIS2IMDRF N60 / N73Japan MHLW
Why ELTON
Subscription TestingAI-NativeFDA ComplianceVerified ExploitabilityELTON vs. Legacy TestingThreat-Led AI PentestingMDDT MethodologyCredentialsDevice ModalitiesPricing
Resources
FDA Deficiency ListFDA Testing RequirementsFDA Cyber SOPs & TemplatesRemediation LibraryRegulatory GuidesWebinarsAI NewsletterThe End of Legacy TestingThe AI Vulnerability ExplosionSecurity AdvisoriesWhitepapersIntelligence & Blog
Company
AboutLeadershipCareersPartnershipsContact Meet ELTON